Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease.

IF 2.3 Q3 CLINICAL NEUROLOGY
Neurology. Clinical practice Pub Date : 2024-04-01 Epub Date: 2024-03-15 DOI:10.1212/CPJ.0000000000200273
Margarethe E Goetz, Cassie B Ford, Melissa A Greiner, Amy Clark, Kim G Johnson, Brystana G Kaufman, Sneha Mantri, Ying Xian, Richard J O'Brien, Emily C O'Brien, Jay B Lusk
{"title":"Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease.","authors":"Margarethe E Goetz, Cassie B Ford, Melissa A Greiner, Amy Clark, Kim G Johnson, Brystana G Kaufman, Sneha Mantri, Ying Xian, Richard J O'Brien, Emily C O'Brien, Jay B Lusk","doi":"10.1212/CPJ.0000000000200273","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>There are racial disparities in health care services received by patients with neurodegenerative diseases, but little is known about disparities in the last year of life, specifically in high-value and low-value care utilization. This study evaluated racial disparities in the utilization of high-value and low-value care in the last year of life among Medicare beneficiaries with dementia or Parkinson disease.</p><p><strong>Methods: </strong>This was a retrospective, population-based cohort analysis using data from North and South Carolina fee-for-service Medicare claims between 2013 and 2017. We created a decedent cohort of beneficiaries aged 50 years or older at diagnosis with dementia or Parkinson disease. Specific low-value utilization outcomes were selected from the Choosing Wisely initiative, including cancer screening, peripheral artery stenting, and feeding tube placement in the last year of life. Low-value outcomes included hospitalization, emergency department visits, neuroimaging services, and number of days receiving skilled nursing. High-value outcomes included receipt of occupational and physical therapy, hospice care, and medications indicated for dementia and/or Parkinson disease.</p><p><strong>Results: </strong>Among 70,650 decedents, 13,753 were Black, 55,765 were White, 93.1% had dementia, and 7.7% had Parkinson disease. Adjusting for age, sex, Medicaid dual enrollment status, rural vs urban location, state (NC and SC), and comorbidities, Black decedents were more likely to receive low-value care including colorectal cancer screening (adjusted hazard ratio [aHR] 1.46 [1.32-1.61]), peripheral artery stenting (aHR 1.72 [1.43-2.08]), and feeding tube placement (aHR 2.96 [2.70-3.24]) and less likely to receive physical therapy (aHR 0.73 [0.64-0.85)], dementia medications (aHR 0.90 [0.86-0.95]), or Parkinson disease medications (aHR 0.88 [0.75-1.02]) within the last year of life. Black decedents were more likely to be hospitalized (aHR 1.28 [1.25-1.32]), more likely to be admitted to skilled nursing (aHR 1.09 [1.05-1.13]), and less likely to be admitted to hospice (aHR 0.82 [0.79-0.85]) than White decedents.</p><p><strong>Discussion: </strong>We found racial disparities in care utilization among patients with neurodegenerative disease in the last year of life, such that Black decedents were more likely to receive specific low-value care services and less likely to receive high-value supportive care than White decedents, even after adjusting for health status and socioeconomic factors.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10955333/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: There are racial disparities in health care services received by patients with neurodegenerative diseases, but little is known about disparities in the last year of life, specifically in high-value and low-value care utilization. This study evaluated racial disparities in the utilization of high-value and low-value care in the last year of life among Medicare beneficiaries with dementia or Parkinson disease.

Methods: This was a retrospective, population-based cohort analysis using data from North and South Carolina fee-for-service Medicare claims between 2013 and 2017. We created a decedent cohort of beneficiaries aged 50 years or older at diagnosis with dementia or Parkinson disease. Specific low-value utilization outcomes were selected from the Choosing Wisely initiative, including cancer screening, peripheral artery stenting, and feeding tube placement in the last year of life. Low-value outcomes included hospitalization, emergency department visits, neuroimaging services, and number of days receiving skilled nursing. High-value outcomes included receipt of occupational and physical therapy, hospice care, and medications indicated for dementia and/or Parkinson disease.

Results: Among 70,650 decedents, 13,753 were Black, 55,765 were White, 93.1% had dementia, and 7.7% had Parkinson disease. Adjusting for age, sex, Medicaid dual enrollment status, rural vs urban location, state (NC and SC), and comorbidities, Black decedents were more likely to receive low-value care including colorectal cancer screening (adjusted hazard ratio [aHR] 1.46 [1.32-1.61]), peripheral artery stenting (aHR 1.72 [1.43-2.08]), and feeding tube placement (aHR 2.96 [2.70-3.24]) and less likely to receive physical therapy (aHR 0.73 [0.64-0.85)], dementia medications (aHR 0.90 [0.86-0.95]), or Parkinson disease medications (aHR 0.88 [0.75-1.02]) within the last year of life. Black decedents were more likely to be hospitalized (aHR 1.28 [1.25-1.32]), more likely to be admitted to skilled nursing (aHR 1.09 [1.05-1.13]), and less likely to be admitted to hospice (aHR 0.82 [0.79-0.85]) than White decedents.

Discussion: We found racial disparities in care utilization among patients with neurodegenerative disease in the last year of life, such that Black decedents were more likely to receive specific low-value care services and less likely to receive high-value supportive care than White decedents, even after adjusting for health status and socioeconomic factors.

患有神经退行性疾病的医疗保险受益人生命最后一年低价值护理的种族差异。
背景和目标:神经退行性疾病患者所接受的医疗服务存在种族差异,但对于生命最后一年的差异,尤其是高价值和低价值医疗服务的使用情况却知之甚少。本研究评估了患有痴呆症或帕金森病的医疗保险受益人在生命最后一年使用高价值和低价值医疗服务的种族差异:这是一项基于人群的回顾性队列分析,使用的数据来自 2013 年至 2017 年期间南北卡罗来纳州的收费服务医疗保险报销单。我们创建了一个死者队列,其中包括确诊患有痴呆症或帕金森病时年龄在 50 岁或以上的受益人。我们从 "明智选择 "倡议(Choosing Wisely initiative)中选取了特定的低价值使用结果,包括癌症筛查、外周动脉支架置入术和生命最后一年的喂食管置入术。低价值结果包括住院、急诊就诊、神经影像服务和接受专业护理的天数。高价值结果包括接受职业和物理治疗、临终关怀以及痴呆症和/或帕金森病药物治疗:在 70,650 名死者中,13,753 人为黑人,55,765 人为白人,93.1% 患有痴呆症,7.7% 患有帕金森病。在对年龄、性别、医疗补助双重登记状态、农村与城市地点、州(北卡罗来纳州和南卡罗来纳州)以及合并症进行调整后,黑人死者更有可能接受低价值护理,包括结肠直肠癌筛查(调整后危险比 [aHR] 1.46 [1.32-1.61])、外周动脉支架植入术(调整后危险比 [aHR] 1.72 [1.43-2.08])。72[1.43-2.08])和喂食管安置(aHR 2.96 [2.70-3.24]),并且在生命的最后一年接受物理治疗(aHR 0.73 [0.64-0.85])、痴呆症药物治疗(aHR 0.90 [0.86-0.95])或帕金森病药物治疗(aHR 0.88 [0.75-1.02])的可能性较低。与白人逝者相比,黑人逝者更有可能住院治疗(aHR 1.28 [1.25-1.32]),更有可能接受专业护理(aHR 1.09 [1.05-1.13]),更不可能接受临终关怀(aHR 0.82 [0.79-0.85]):讨论:我们发现神经退行性疾病患者在生命最后一年的护理利用方面存在种族差异,即使在调整了健康状况和社会经济因素后,与白人死者相比,黑人死者更有可能接受特定的低价值护理服务,而接受高价值支持性护理的可能性较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurology. Clinical practice
Neurology. Clinical practice CLINICAL NEUROLOGY-
CiteScore
4.00
自引率
0.00%
发文量
77
期刊介绍: Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信